BioWorld

Feb. 15, 2010

View Archived Issues

Safety Brouhaha Tests 'Mettle' of Feraheme After Downgrade

Alexza Just See: Biovail Deal Spotlights AZ-004's Way Forth

Money Raised By Biotech in 2010

Week in Review

Word on the Street

Week in Washington

FDA Approvals In January

Phase I Clinical Trials Update: January 2010

Phase II Clinical Trials Update: January 2010

Pivotal/Phase III Clinical Trials Update: February 2010

Non-U.S. Clinical Trials And Regulatory Actions: February 2010

Celera's Hidden Treasure: A 'Royal' Road to Payoff?

Last week, the Biotechnology Value Fund (BVF) proposed that Celera Corp. separate its low margin diagnostics business from its potentially high-margin drug royalty stream. Read More

Money Raised Year to Date

FDA Submissions, Approvals And Other Actions: February 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...